NFE2L2 and non-small cell lung carcinoma: Another prominent advance for the study of NRF2 in NSCLC includes identification of a small molecule chemical inhibitor, ML385, which inhibits NRF2 DNA binding, as well as expression of itself and downstream target genes.38